Cargando…

Tau oligomers in cerebrospinal fluid in Alzheimer's disease

OBJECTIVE: With an increasing incidence of Alzheimer's disease (AD) and neurodegenerative tauopathies, there is an urgent need to develop reliable biomarkers for the diagnosis and monitoring of the disease, such as the recently discovered toxic tau oligomers. Here, we aimed to demonstrate the p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sengupta, Urmi, Portelius, Erik, Hansson, Oskar, Farmer, Kathleen, Castillo‐Carranza, Diana, Woltjer, Randall, Zetterberg, Henrik, Galasko, Douglas, Blennow, Kaj, Kayed, Rakez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5376754/ https://www.ncbi.nlm.nih.gov/pubmed/28382304 http://dx.doi.org/10.1002/acn3.382

Ejemplares similares

Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy
por: Gerson, Julia E., et al.
Publicado: (2018)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

α-Synuclein Oligomers Induce a Unique Toxic Tau Strain
por: Castillo-Carranza, Diana L., et al.
Publicado: (2018)

Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2011)

Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau
por: Lasagna-Reeves, Cristian A., et al.
Publicado: (2012)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy
por: Sengupta, Urmi, et al.
Publicado: (2016)

Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases
por: Nilson, Ashley N., et al.
Publicado: (2016)

Tau oligomers mediate aggregation of RNA‐binding proteins Musashi1 and Musashi2 inducing Lamin alteration
por: Montalbano, Mauro, et al.
Publicado: (2019)

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias
por: Cicognola, Claudia, et al.
Publicado: (2021)

Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies
por: Castillo-Carranza, Diana L, et al.
Publicado: (2017)

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease
por: Hall, Sara, et al.
Publicado: (2016)

Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies
por: Moore, Kenya, et al.
Publicado: (2023)

Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
por: Cicognola, Claudia, et al.
Publicado: (2018)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Lysine 63-linked ubiquitination of tau oligomers contributes to the pathogenesis of Alzheimer’s disease
por: Puangmalai, Nicha, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin and YKL‐40 as biomarkers of Alzheimer's disease
por: Janelidze, Shorena, et al.
Publicado: (2015)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia
por: Gaikwad, Sagar, et al.
Publicado: (2021)

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein
por: Zettergren, Anna, et al.
Publicado: (2019)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies
por: Puangmalai, Nicha, et al.
Publicado: (2020)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015)

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: Their Role in Clinical Chemistry
por: Blennow, Kaj, et al.
Publicado: (2000)

Confounding Factors Influencing Amyloid Beta Concentration in Cerebrospinal Fluid
por: Bjerke, Maria, et al.
Publicado: (2010)

Pathological tau signatures and nuclear alterations in neurons, astrocytes and microglia in Alzheimer's disease, progressive supranuclear palsy, and dementia with Lewy bodies
por: Montalbano, Mauro, et al.
Publicado: (2022)

Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
por: Gisslén, Magnus, et al.
Publicado: (2009)

Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives
por: Lo Cascio, Filippa, et al.
Publicado: (2019)

The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes
por: Lasagna-Reeves, Cristian A, et al.
Publicado: (2014)

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2020)

Polymorphic α-Synuclein Strains Modified by Dopamine and Docosahexaenoic Acid Interact Differentially with Tau Protein
por: Sengupta, Urmi, et al.
Publicado: (2020)

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer’s disease patients and healthy controls
por: Kvartsberg, Hlin, et al.
Publicado: (2015)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Truncating tau reveals different pathophysiological actions of oligomers in single neurons
por: Hill, Emily, et al.
Publicado: (2021)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_duclov0p6mq5ssovk0mcjsh2i9